Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech that has proved helpful hard but unsuccessfully to produce an one off therapy, variously referred to as Pro 140, leronlimab, as well as Vyrologix.

In development of this particular therapy, CytoDyn has cast its net far and wide both geographically and in terms of potential indications.

CytoDyn’s inventories of leronlimab are building up, whether they’ll actually be being used is actually an open question.

While CYDY  happens to be dawdling, promote opportunities for leronlimab as being a combination treatment in the curing of multi-drug-resistant HIV have been closing.

I’m composing my fifteenth CytoDyn (OTCQB:CYDY) report on FintechZoom to celebrate the sale made of my past several shares. My 1st CytoDyn article, “CytoDyn: What To Do When It’s Too Good to be able to Be True?”, set out the following prediction:

Instead I expect it to be a serial disappointer. CEO Pourhassan offered such a very promotional picture in the Uptick Newswire interview that I came away with a bad impression of the company.

Irony of irony, the poor impression of mine of the company has grown steadily, yet the disappointment has not been financial. Two decades ago CytoDyn was trading <$1.00. On 2/19/20 as I create, it trades at $5.26; my closing transaction was on 2/11/21 > $6.00.

What manner of stock  is this that delivers a > 6 bagger yet still disappoints? Therein is the story; let me explain.

CytoDyn acquired its much storied treatment (which I shall refer to as leronlimab) returned during 2012, announced as follows:

CytoDyn Inc…. has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) looking for the CCR5 receptor for the treatment and reduction of HIV, coming from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical development mAb with demonstrated anti-viral activity of HIV infected subjects. Today’s payment of $3.5 million transfers ownership of the know-how and linked intellectual property from Progenics to CytoDyn, and approximately 25 million mg of bulk drug substance…. milestone payments upon commencement of a stage III clinical trial ($1.5 huge number of) and also the first new drug application endorsement ($five million), and also royalty payments of five percent of net sales upon commercialization.

Since that moment, CytoDyn’s guiding nous, Nader Pourhassan [NP] has turned this inauspicious acquisition right into a springboard for CytoDyn to acquire a market place cap > $3.5 billion. It has done so in exclusive reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Instead of having a pipeline with many therapies and numerous indications, it has this individual therapy and a “broad pipeline of indications” because it puts it. I call such pipelines, “pipedots.” In CytoDyn’s situation it touts its leronlimab as a potentially beneficial therapy in dozens of indications.

The opening banner of its on its site (below) shows an active business with diverse interests albeit centered on leronlimab, several disease types, multiple publications in addition to multiple delivering presentations.

Could all of it be smoke and mirrors? That’s a question I have been asking myself through the really start of my interest in this business. Judging with the multiples of a huge number of several responses on listings accessible via Seeking Alpha’s CytoDyn Summary webpage, I’m a lot from alone in this particular question.

CytoDyn is a traditional battleground, or some may say cult inventory. Its adherents are fiercely shielding of its prospects, quick to label some bad opinions as scurrilous short-mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *